Titan Pharmaceuticals

Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

Retrieved on: 
Thursday, January 25, 2024
Titan, SAN, Titan Pharmaceuticals, Letter

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that by letter dated January 24, 2024, the Company was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that by letter dated January 24, 2024, the Company was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market.
  • As such, the listing matter has been closed.

Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

Retrieved on: 
Thursday, December 28, 2023
Titan, Transfer, File, SAN, CUSIP, Titan Pharmaceuticals, Shareholder, Amendment, Security (finance)

The Company's stockholders approved the reverse stock split at a Special Meeting of Stockholders on December 27, 2023.

Key Points: 
  • The Company's stockholders approved the reverse stock split at a Special Meeting of Stockholders on December 27, 2023.
  • The reverse stock split will not modify the rights or preferences of the common stock.
  • The Company has appointed its transfer agent, Continental Stock Transfer & Trust Company (“Continental”), to act as exchange agent for the reverse stock split.
  • Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to brokers' particular processes.

Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

Retrieved on: 
Monday, October 16, 2023
Business studies, Swinburne University of Technology, Dell, PwC, Massey University, Titan Pharmaceuticals, Electronics, Black, SAN, Disagreement, Private company limited by shares, Management, Titan, Multimedia

SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato’ Seow Gim Shen and Brynner Chiam to the Company’s Board of Directors, effective October 12, 2023.

Key Points: 
  • SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato’ Seow Gim Shen and Brynner Chiam to the Company’s Board of Directors, effective October 12, 2023.
  • Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately.
  • These resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.
  • Dato’ Seow Gim Shen obtained his Bachelor of Multimedia from Swinburne University of Technology in 2005.

Ashvattha Therapeutics Announces Appointment of Dr. Sakura Minami as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations

Retrieved on: 
Monday, October 9, 2023
Titan, Nanomedicine, Ophthalmology, ALS, Neuroscience, Senior, Ashvattha, University of California, Irvine School of Medicine, University of Colorado Boulder Computer Science Department, Amgen, Research, Neuro, DME, Inflammation, Therapy, Neurology, IND, Titan Pharmaceuticals, CV, Grifols, AMD, University, Georgetown University, Laboratory, Microglia, Head, Macrophage, Pfizer, System, StemCells, Inc., Translational medicine, Patient, Pharmaceutical industry, Recode

REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.
  • Ms. Thayer has more than 20 years of progressive leadership experience in clinical development operations across various therapeutic areas from Phase 1 through Phase 3.
  • She previously served as Vice President, Head of Clinical Operations at Recode Therapeutics where she established the clinical operations function at the company.
  • Prior to Recode, she led clinical operations at Global Blood Therapeutics (Pfizer), StemCells Inc, FivePrime Therapeutics (Amgen), CV Therapeutics (Gilead), Titan Pharmaceuticals and Becton Dickinson Immunocytometry Systems.

Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

Retrieved on: 
Monday, September 18, 2023
Titan Pharmaceuticals, Certificate, Sale, Sales management, SAN, Asset purchase agreement, Regulation, Security (finance), Titan

SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd. (“Sire Group”) for the sale of the Company’s newly designated Series AA Convertible Preferred Stock (the “Preferred Stock”).

Key Points: 
  • SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd. (“Sire Group”) for the sale of the Company’s newly designated Series AA Convertible Preferred Stock (the “Preferred Stock”).
  • Sire Group purchased 950,000 shares of Preferred Stock for an aggregate purchase price of $9,500,000, consisting of (i) $5 million in cash at closing and (ii) $4.5 million in the form of a promissory note from Sire Group, personally guaranteed by a principal of Sire Group, due and payable on September 23, 2023, subject to two 10-day extensions.
  • Titan and Sire Group have concurrently entered into a registration rights agreement (the “Registration Rights Agreement”) pursuant to which Titan has agreed to provide certain registration rights upon the occurrence of certain events set forth in the Registration Rights Agreement.
  • Additional information regarding the agreement can be found in an 8-K that was filed with the SEC: https://ir.titanpharm.com/all-sec-filings .

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

Retrieved on: 
Thursday, July 27, 2023
Agreement, Employment, Sale, Opioid use disorder, Delaware General Corporation Law, SAN, Itch, Nalmefene, Proneura prolongata, Pharmaceutical industry, Titan Pharmaceuticals, Buprenorphine, Titan

SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology.

Key Points: 
  • SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology.
  • Under the terms of the Agreement, Fedson will purchase the ProNeura assets from Titan for an upfront purchase price of $2 million ($1 million at closing, $1 million to be held in escrow pending completion of certain conditions) with potential milestone payments to Titan of up to $50 million on future net sales of the products.
  • Titan would also receive single digit royalties on future net sales of the products.
  • “We are pleased to announce the sale of these potentially lifesaving assets to Fedson,” stated David E. Lazar, Chief Executive Officer of Titan Pharmaceuticals.

Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant

Retrieved on: 
Tuesday, July 5, 2022
FDA, Opioid use disorder, Addiction medicine, Securities Act of 1933, Securities Exchange Act of 1934, National Institute, Investigational New Drug, Marketing, Titan Pharmaceuticals, OUD, SAN, Food, IND, Drug Quality and Security Act, CA, Medication, NIDA, NASDAQ, Patent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Titan, Proneura prolongata

Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan, commented, "FDA clearance of the IND for our ProNeura-based nalmefene implant marks an important milestone in developing a novel product that may help answer the call for long-term treatment options in addiction medicine.

Key Points: 
  • Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan, commented, "FDA clearance of the IND for our ProNeura-based nalmefene implant marks an important milestone in developing a novel product that may help answer the call for long-term treatment options in addiction medicine.
  • We are very grateful for the support we received from the National Institute for Drug Addiction, or NIDA, that enabled us to meet this objective."
  • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeuralong-term, continuous drug delivery technology.
  • In December 2021, Titan commenced a process to explore and evaluate strategic alternatives to enhance shareholder value.

Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.

Retrieved on: 
Friday, June 10, 2022
Titan, Board, Activism, GLOBE, Titan Pharmaceuticals, Â, Company, Director, NASDAQ, Schedule 13D

As a result of our belief in the prospects of the Company and its ability to unlock significant stockholder value through a strategic transaction, we filed an amendment to our Schedule 13D yesterday disclosing an increase in our already sizeable position in the Company to 9.9% of TTNPs outstanding shares.

Key Points: 
  • As a result of our belief in the prospects of the Company and its ability to unlock significant stockholder value through a strategic transaction, we filed an amendment to our Schedule 13D yesterday disclosing an increase in our already sizeable position in the Company to 9.9% of TTNPs outstanding shares.
  • We remain hopeful that the Companys strategic review will result in a positive outcome that is in the best interest of all TTNP stockholders.
  • Activist Investing LLC is an investment fund specializing in reverse merger and other event-driven opportunities.
  • Its Chief Executive Officer,David E. Lazar, brings domestic and international experience in operations, accounting, audit preparation, due diligence, capital restructuring, debt financing, and mergers and acquisitions.